生物
癌症研究
阿布勒
酪氨酸激酶
布鲁顿酪氨酸激酶
伊马替尼
ETV6
信号转导
髓系白血病
细胞生物学
遗传学
基因
染色体易位
作者
Olga Zimmermannová,Eliska Doktorova,Jan Stuchlý,Veronika Kanderová,Daniela Kužílková,Hynek Strnad,Júlia Starková,Meritxell Alberich-Jordà,J.H. Frederik Falkenburg,Jan Trka,Jir̆í Petrák,Jan Zuna,Marketa Kubricanova Zaliova
出处
期刊:Oncogene
[Springer Nature]
日期:2017-06-26
卷期号:36 (43): 5985-5994
被引量:36
摘要
Leukemias harboring the ETV6-ABL1 fusion represent a rare subset of hematological malignancies with unfavorable outcomes. The constitutively active chimeric Etv6-Abl1 tyrosine kinase can be specifically inhibited by tyrosine kinase inhibitors (TKIs). Although TKIs represent an important therapeutic tool, so far, the mechanism underlying the potential TKI resistance in ETV6-ABL1 -positive malignancies has not been studied in detail. To address this issue, we established a TKI-resistant ETV6-ABL1 -positive leukemic cell line through long-term exposure to imatinib. ETV6-ABL1 -dependent mechanisms (including fusion gene/protein mutation, amplification, enhanced expression or phosphorylation) and increased TKI efflux were excluded as potential causes of resistance. We showed that TKI effectively inhibited the Etv6-Abl1 kinase activity in resistant cells, and using short hairpin RNA (shRNA)-mediated silencing, we confirmed that the resistant cells became independent from the ETV6-ABL1 oncogene. Through analysis of the genomic and proteomic profiles of resistant cells, we identified an acquired mutation in the GNB1 gene, K89M, as the most likely cause of the resistance. We showed that cells harboring mutated GNB1 were capable of restoring signaling through the phosphoinositide-3-kinase (PI3K)/Akt/mTOR and mitogen-activated protein kinase (MAPK) pathways, whose activation is inhibited by TKI. This alternative GNB1 K89M -mediated pro-survival signaling rendered ETV6-ABL1 -positive leukemic cells resistant to TKI therapy. The mechanism of TKI resistance is independent of the targeted chimeric kinase and thus is potentially relevant not only to ETV6-ABL1 -positive leukemias but also to a wider spectrum of malignancies treated by kinase inhibitors.
科研通智能强力驱动
Strongly Powered by AbleSci AI